| Methods |
Randomized, double‐blind trial |
| Participants |
Inpatients less than 1 year old with acute bronchiolitis. Mean age 4.3 months, 61% male, 68% RSV‐positive
Country: UK |
| Interventions |
6‐hourly nebulized solutions of 250 µg of ipratropium bromide in 2 ml saline (n = 34) or normal saline alone (n = 32) |
| Outcomes |
Day to improvement in study specific clinical score. 4‐point score for each of heart rate, respiratory rate, cough, rhinitis, nasal flaring, cyanosis, hyperinflation, tracheal tug, intercostal recession, subcostal recession, respiratory distress, crepitations and rhonchi. Side effects: increased heart rate, persistent coughing |
| Notes |
— |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
High risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Blinding (performance bias and detection bias)
All outcomes |
Low risk |
|
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
Incomplete data |
| Selective reporting (reporting bias) |
High risk |
Yes |
